Prostate Cancer
A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.
November 26, 2024
Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.
November 26, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease.
November 26, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.
November 26, 2024
Prioritizing precision: detection of prostate cancer using mri guided fusion needle biopsy across the pennsylvania urologic regional collaborative.
November 26, 2024
Discrimination against Gay and Bisexual Patients in Prostate Cancer Treatment: Results from the Restore-2 Study.
November 26, 2024
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
November 25, 2024
PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.
November 25, 2024
Association of Race and Area of Deprivation Index with Prostate Cancer Incidence and Lethality.
November 25, 2024
Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective.
November 25, 2024
Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.
November 25, 2024
Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.
November 22, 2024